Results 141 to 150 of about 137,068 (205)

Mapping the global research output of Traditional Chinese Medicine in the treatment of metabolic dysfunction-associated steatotic liver disease: a comprehensive bibliometric analysis based on multiple databases (2000-2025). [PDF]

Front Med (Lausanne)
Wang D, Li M, Zhao R, Wang H, Chen H, Huang M, Shen Y, Ma L.   +7 more
europepmc   +1 more source

Histological features of liver biopsy in patients with COVID-19: a single institution experience with long term follow-up outcome. [PDF]

Diagn Pathol
Chi Z, Moghal N, Rakheja D, Peng L.
europepmc   +1 more source

Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis. [PDF]

JHEP Rep
Marquardt J, Ota R, Sebastiani G, Baca DM, Smith E, Wallinger H, Tebbs K, Quinones E, Amari L, Bugianesi E.   +9 more
europepmc   +1 more source

The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. [PDF]

Pharmaceutics
Tornea DA, Goldis C, Isaic A, Motofelea AC, Sima AC, Ciocarlie T, Crintea A, Diaconescu RG, Motofelea N, Goldis A.   +9 more
europepmc   +1 more source

Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis. [PDF]

Hepatol Commun
Younossi ZM, Nader F, Labriola D, Taub R, Racila A, Henry L, Stepanova M.   +6 more
europepmc   +1 more source

MASH and the race for liver antifibrotics. [PDF]

Front Gastroenterol (Lausanne)
Wills Q.
europepmc   +1 more source

Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study. [PDF]

J Clin Med
Mihăilă D, Domnariu HP, Moga DF, Domnariu CD.   +3 more
europepmc   +1 more source